专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070202127A1 Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids 审中-公开
标题翻译：编码DP-178的核酸和用于治疗辅助物质的其他病毒融合抑制剂肽
公开(公告)号：US20070202127A1
公开(公告)日：2007-08-30
申请号：US11529806
申请日：2006-09-28
申请人： Dani Bolognesi , Thomas Matthews , Carl Wild , Shawn Barney , Dennis Lambert , Stephen Petteway , Alphonse Langlois
发明人： Dani Bolognesi , Thomas Matthews , Carl Wild , Shawn Barney , Dennis Lambert , Stephen Petteway , Alphonse Langlois
IPC分类号： C12Q1/68 , A61K39/21 , A61K39/12
CPC分类号： C07K14/31 , A61K38/00 , A61K39/00 , A61K2039/525 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0817 , C07K5/0819 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1021 , C07K5/1024 , C07K14/005 , C07K14/21 , C07K14/22 , C07K14/285 , C07K2319/00 , C12N2710/16222 , C12N2730/10122 , C12N2740/13022 , C12N2740/15022 , C12N2740/16222 , C12N2760/16122 , C12N2760/18122 , C12N2760/18422 , C12N2760/18522 , C12N2760/18622 , C12N2760/18722
摘要： The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
摘要翻译：本发明涉及显示出有力的抗逆转录病毒活性的肽。本发明的肽包含对应于HIV-1细胞gp41蛋白的氨基酸638至673的DP178（SEQ ID：1）肽以及DP178的片段，类似物和同系物。本发明还涉及这样的肽的用途，例如抑制人和非人类逆转录病毒，特别是HIV，向未感染细胞的传播。

2. 发明授权

US06277974B1 Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death 失效
公开(公告)号：US06277974B1
公开(公告)日：2001-08-21
申请号：US09461697
申请日：1999-12-14
申请人： Donald C. Lo , Shawn Barney , Mary Beth Thomas , Stuart D. Portbury , Kasturi Puranam , Lawrence C. Katz
发明人： Donald C. Lo , Shawn Barney , Mary Beth Thomas , Stuart D. Portbury , Kasturi Puranam , Lawrence C. Katz
IPC分类号： C07H2102
CPC分类号： C07K14/4747
摘要： The present invention relates to compositions and methods for the treatment and diagnosis of conditions, disorders, or diseases involving cell death. The invention encompasses protective nucleic acids which, when introduced into a cell predisposed to undergo cell death or in the process of undergoing cell death, prevent, delay, or rescue the cell from death relative to a corresponding cell into which no exogenous nucleic acids have been introduced. The invention encompasses nucleic acids of the protective sequence, host cell expression systems of the protective sequence, and hosts that have been transformed by these expression systems, including transgenic animals. The invention also encompasses novel protective sequence products, including proteins, polypeptides and peptides containing amino acid sequences of the proteins, fusion proteins of proteins, polypeptides and peptides, and antibodies directed against such gene products. The invention further relates to target sequences, including upstream and downstream regulatory sequences or complete gene sequences, antibodies, antisense molecules or sequences, ribozyme molecules, and other inhibitors or modulators directed against such protective sequences, protective sequence products, genes, gene products, and/or their regulatory elements involved in cell death. The present invention also relates to methods and compositions for the diagnosis and treatment of conditions, disorders, or diseases, involving cell death, including, but not limited to, treatment of the types of conditions, disorders, or diseases, which can be prevented, delayed or rescued from cell death and include, but are not limited to, those associated with the central nervous system, including neurological and psychiatric conditions, disorders, or diseases, and those of the peripheral nervous system. Further, the invention relates to methods of using the protective sequence, protective sequence products, and/or their regulatory elements for the identification of compounds that modulate the expression of the protective sequence and/or the activity of the protective sequence product. Such compounds can be useful as therapeutic agents in the treatment of various conditions, disorders, or diseases involving cell death.

3. 发明授权

US06258782B1 Hybrid polypeptides with enhanced pharmacokinetic properties 失效
标题翻译：具有增强的药代动力学性质的杂交多肽
公开(公告)号：US06258782B1
公开(公告)日：2001-07-10
申请号：US09082279
申请日：1998-05-20
申请人： Shawn Barney , Kelly I. Guthrie , Gene Merutka , Mohmed K. Anwer , Dennis M. Lambert
发明人： Shawn Barney , Kelly I. Guthrie , Gene Merutka , Mohmed K. Anwer , Dennis M. Lambert
IPC分类号： A61K3816
CPC分类号： C07K14/005 , A61K38/00 , A61K47/62 , C07K5/1021 , C07K5/1024 , C07K14/59 , C07K2319/00 , C12N2740/16122 , C12N2760/18522
摘要： The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
摘要翻译：本发明涉及最初衍生自增强其所连接的核心多肽的药代动力学性质的各种逆转录病毒包膜（gp41）蛋白质序列的增强子肽序列。本发明基于以下发现：包含与核心多肽连接的增强子肽序列的杂合多肽具有增强的药代动力学性质，例如增加的半衰期。本发明还涉及通过将增强子肽序列与核心多肽连接来增强任何核心多肽的药代动力学性质的方法。用于本发明实践的核心多肽可包括可用于例如治疗或预防试剂的任何药理学上有用的肽。

4. 发明申请

US20070037141A1 Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission 审中-公开
标题翻译：用于抑制膜融合相关事件（包括HIV传播）的方法和组合物
公开(公告)号：US20070037141A1
公开(公告)日：2007-02-15
申请号：US10739355
申请日：2003-12-17
申请人： Darii Bolognesi , Thomas Matthews , Carl Wild , Shawn Barney , Dennis Lambert , Stephen Petteway , Alphonse Langlois
发明人： Darii Bolognesi , Thomas Matthews , Carl Wild , Shawn Barney , Dennis Lambert , Stephen Petteway , Alphonse Langlois
IPC分类号： C12Q1/70
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/525 , A61K2039/555 , A61K2039/60 , A61K2039/6031 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0817 , C07K5/0819 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1021 , C07K5/1024 , C07K14/21 , C07K14/22 , C07K14/245 , C07K14/285 , C07K14/31 , C07K2319/00 , C12N7/00 , C12N2710/16222 , C12N2730/10122 , C12N2740/13022 , C12N2740/14022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2740/17022 , C12N2760/16122 , C12N2760/18022 , C12N2760/18122 , C12N2760/18422 , C12N2760/18522 , C12N2760/18622 , C12N2760/18722 , G01N33/5008 , G01N33/502 , G01N33/505 , G01N33/5091 , Y10S530/826
摘要： The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
摘要翻译：本发明涉及显示出有力的抗逆转录病毒活性的肽。本发明的肽包含对应于HIV-1细胞gp41蛋白的氨基酸638至673的DP178（SEQ ID：1）肽以及DP178的片段，类似物和同系物。本发明还涉及这样的肽的用途，例如抑制人和非人类逆转录病毒，特别是HIV，向未感染细胞的传播。

5. 发明授权

US06656906B1 Hybrid polypeptides with enhanced pharmacokinetic properties 失效
公开(公告)号：US06656906B1
公开(公告)日：2003-12-02
申请号：US09350641
申请日：1999-07-09
申请人： Shawn Barney , Kelly I. Guthrie , Gene Merutka , Mohmed K. Anwer , Dennis M. Lambert
发明人： Shawn Barney , Kelly I. Guthrie , Gene Merutka , Mohmed K. Anwer , Dennis M. Lambert
IPC分类号： A61K3816
CPC分类号： C07K14/005 , A61K38/00 , A61K47/62 , C07K5/1021 , C07K5/1024 , C07K14/59 , C07K2319/00 , C12N2740/16122 , C12N2760/18522 , Y02A50/465
摘要： The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.

6. 发明授权

US06333395B1 Compositions for inhibition of membrane fusion-associated events, including human parainfluenza virus transmission 失效
标题翻译：用于抑制膜融合相关事件的组合物，包括人副流感病毒传播
公开(公告)号：US06333395B1
公开(公告)日：2001-12-25
申请号：US08474349
申请日：1995-06-07
申请人： Shawn Barney , Dennis Lambert , Stephen Robert Petteway
发明人： Shawn Barney , Dennis Lambert , Stephen Robert Petteway
IPC分类号： C12N14115
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/525 , A61K2039/555 , A61K2039/60 , A61K2039/6031 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0817 , C07K5/0819 , C07K5/1008 , C07K5/101 , C07K5/1013 , C07K5/1016 , C07K5/1021 , C07K5/1024 , C07K14/21 , C07K14/22 , C07K14/245 , C07K14/285 , C07K14/31 , C07K2319/00 , C12N7/00 , C12N2710/16222 , C12N2730/10122 , C12N2740/13022 , C12N2740/14022 , C12N2740/15022 , C12N2740/16122 , C12N2740/16222 , C12N2740/17022 , C12N2760/16122 , C12N2760/18022 , C12N2760/18122 , C12N2760/18422 , C12N2760/18522 , C12N2760/18622 , C12N2760/18722 , G01N33/5008 , G01N33/502 , G01N33/505 , G01N33/5091 , Y10S530/826
摘要： The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
摘要翻译：本发明涉及显示出有力的抗逆转录病毒活性的肽。本发明的肽包含对应于HIV-1LAI gp41蛋白的氨基酸638至673的DP178（SEQ ID NO：1）肽以及DP178的片段，类似物和同系物。本发明还涉及这样的肽的用途，例如抑制人和非人类逆转录病毒，特别是HIV，向未感染细胞的传播。

7. 发明授权

US07297784B2 DNA encoding T-1249 and other viral fusion inhibitor peptides useful for treating aids 失效
标题翻译：编码T-1249的DNA和其他可用于治疗辅助物质的病毒融合抑制剂肽
公开(公告)号：US07297784B2
公开(公告)日：2007-11-20
申请号：US10351641
申请日：2003-01-24
申请人： Shawn Barney , Kelly I. Guthrie , Gene Merutka , Mohmed K. Anwer , Dennis M. Lambert
发明人： Shawn Barney , Kelly I. Guthrie , Gene Merutka , Mohmed K. Anwer , Dennis M. Lambert
IPC分类号： C07H21/04 , A61K39/21
CPC分类号： C07K14/005 , A61K38/00 , A61K47/62 , C07K5/1021 , C07K5/1024 , C07K14/59 , C07K2319/00 , C12N2740/16122 , C12N2760/18522 , Y02A50/465
摘要： The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
摘要翻译：本发明涉及最初衍生自增强其所连接的核心多肽的药代动力学性质的各种逆转录病毒包膜（gp41）蛋白质序列的增强子肽序列。本发明基于以下发现：包含与核心多肽连接的增强子肽序列的杂合多肽具有增强的药代动力学性质，例如增加的半衰期。本发明还涉及通过将增强子肽序列与核心多肽连接来增强任何核心多肽的药代动力学性质的方法。用于本发明实践的核心多肽可包括可用于例如治疗或预防试剂的任何药理学上有用的肽。

8. 发明授权

US06562787B1 Hybrid polypeptides with enhanced pharmacokinetic properties 失效
公开(公告)号：US06562787B1
公开(公告)日：2003-05-13
申请号：US09834784
申请日：2001-04-13
申请人： Shawn Barney , Kelly I. Guthrie , Gene Merutka , Mohmed K. Anwer , Dennis M. Lambert
发明人： Shawn Barney , Kelly I. Guthrie , Gene Merutka , Mohmed K. Anwer , Dennis M. Lambert
IPC分类号： A61K3816
CPC分类号： C07K14/005 , A61K38/00 , A61K47/62 , C07K5/1021 , C07K5/1024 , C07K14/59 , C07K2319/00 , C12N2740/16122 , C12N2760/18522
摘要： The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.

9. 发明授权

US06348568B1 Hybrid polypeptides with enhanced pharmacokinetic properties 失效
标题翻译：具有增强的药代动力学性质的杂交多肽
公开(公告)号：US06348568B1
公开(公告)日：2002-02-19
申请号：US09315304
申请日：1999-05-20
申请人： Shawn Barney , Kelly I. Guthrie , Gene Merutka , Mohmed K. Anwer , Dennis M. Lambert
发明人： Shawn Barney , Kelly I. Guthrie , Gene Merutka , Mohmed K. Anwer , Dennis M. Lambert
IPC分类号： C07K200
CPC分类号： C07K14/005 , A61K38/00 , A61K47/62 , C07K5/1021 , C07K5/1024 , C07K14/59 , C07K2319/00 , C12N2740/16122 , C12N2760/18522
摘要： The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
摘要翻译：本发明涉及最初衍生自增强其所连接的核心多肽的药代动力学性质的各种逆转录病毒包膜（gp41）蛋白质序列的增强子肽序列。本发明基于以下发现：包含与核心多肽连接的增强子肽序列的杂合多肽具有增强的药代动力学性质，例如增加的半衰期。本发明还涉及通过将增强子肽序列与核心多肽连接来增强任何核心多肽的药代动力学性质的方法。用于本发明实践的核心多肽可包括可用于例如治疗或预防试剂的任何药理学上有用的肽。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式